{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-041191","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2026-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.819951+00:00","generated_at":"2026-05-16T04:02:36.002486+00:00","sec_items":["3.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"confidence":"high","headline":"Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell","bullets":["Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.","Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.","Company has requested hearing to appeal delisting; stay in effect pending panel decision.","CEO and CFO now consultants; no ongoing operations after workforce reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-041191","json":"https://secwatch.observer/filing/0001193125-26-041191.json","markdown":"https://secwatch.observer/filing/0001193125-26-041191.md","text":"https://secwatch.observer/filing/0001193125-26-041191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/0001193125-26-041191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/d157841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:02:36.002486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}